Clinical Trial Update: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dapagliflozin for reducing worsening heart failure or cardiovascular death in chronic heart failure with reduced ejection fraction; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) | Phase 3 | Status: COMPLETED | Results posted: 2020-09-01